DiaSorin Molecular has announced the expansion of its menu of molecular reagents with the introduction of a Pneumocystis jirovecii primer pair for use in laboratory-developed molecular tests. This analyte-specific reagent (ASR) can be used for the amplification and detection of the Pneumocystis jirovecii mtLSU gene with a CFR610- and BHQ-2-labeled probe and forward and reverse primers. This is DiaSorin’s first fungal infectious disease target.
The new primer pair joins DiaSorin’s menu of more than 60 molecular reagents that can be used to detect bacterial and viral targets in addition to human genetic mutations. The primer pairs are classified as analyte-specific reagents, which are used by high-complexity laboratories to develop their own lab-developed tests (LDTs).
“This new primer pair is the result of our ongoing work to develop and deliver a robust menu of molecular products,” said Michelle Tabb, vice president of research and development for DiaSorin Molecular. “With greater access to commercially developed molecular reagents, diagnostic labs are better able to customize tests that meet their unique patient needs.”
Oxford Gene Technology has announced that its new facility in Cambridge, UK, has achieved Medical Device Single Audit Program certification of its quality management system, further solidifying the company’s aim to reach into molecular diagnostic markets.